Healthcare Technology Company Announces Positive Clinical Update From Cancer Trial

Lantern Pharma, a company specializing in the use of artificial intelligence (AI) for the development of cancer therapies, has recently shared promising preliminary results from its ongoing Phase 2 HARMONIC™ clinical trial. This study focuses on never smokers with advanced NSCLC, specifically lung adenocarcinoma, who have developed resistance to tyrosine kinase inhibitors (TKIs). The aim of the trial is to enhance patient outcomes through the combination of LP-300 and standard-of-care chemotherapy. $Lantern Pharma (LTRN.US)$